Jacob Gottlieb is joining forces with a former teammate and mentor. He and Stuart Weisbrod were very successful together as Healthcare investors. The two men initially met at Merlin Biomed Group. Weisbrod was a high-ranking member of the organization while Gottlieb was a portfolio manager for Stuart. Weisbrod had a high level of expertise that shaped the way Gottlieb would view the business from that point forward. Jacob Gottlieb went on to do great work for Merlin, helping the company achieve great returns in 1999 and 2000. He assisted with bringing in key clients up until the company closed for business in 2007.
Jacob Gottlieb went on to have success in the finance industry. He launched his own company called Visium Asset Management with a 300 million dollar investment. Gottlieb quickly pushed the company’s value to 2.5 billion dollars. He survived the financial crisis in 2008 and led Visium on a path of continued success. The organization eventually grew into an 8 billion dollar hedge fund. Visium has over 200 employees with offices in cities around the world including London, New York and San Francisco.
Visium was a shining example of success for roughly 10 years. The company fell on hard times in 2016 when three of its executives were accused of insider trading. They were thoroughly investigated and reported to the FBI by a whistle-blower working on the inside. The authorities took time to mount all of the evidence and eventually brought charges against several employees at Visium.
Jacob Gottlieb was never charged with any crime or ethical wrongdoing. He remains with the company as its CEO and has worked to return funds to its investors. Gottlieb is in place to wind down the company while it is being watched over by the SEC.
Jacob Gottlieb has moved forward in his career and formed a new enterprise called Altium Capital. Altium Capital is a hedge fund that will be Gottlieb’s latest statement. The company already holds great value due to Gottlieb’s previous success in the industry. It has recently made a stake investment in Oramed Pharmaceuticals Inc.